<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558296</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-476</org_study_id>
    <nct_id>NCT02558296</nct_id>
  </id_info>
  <brief_title>Bexagliflozin Efficacy and Safety Trial</brief_title>
  <acronym>BEST</acronym>
  <official_title>A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of bexagliflozin in lowering&#xD;
      hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased&#xD;
      risk of cardiovascular adverse events.&#xD;
&#xD;
      The data from this study will be combined with the data from other bexagliflozin studies in a&#xD;
      meta-analysis of CV safety outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 130 investigative sites globally are planned to participate in this study.&#xD;
&#xD;
      An estimated 1650 subjects with inadequately controlled T2DM and an elevated risk of&#xD;
      cardiovascular adverse events will be randomized to bexagliflozin tablets, 20 mg, or placebo&#xD;
      in a ratio of 2:1 in addition to the background anti-diabetic medications.&#xD;
&#xD;
      The study is an event-driven trial. The treatment period will end when the last randomized&#xD;
      subject has completed at least 52 weeks of treatment and a total of at least 134 subjects&#xD;
      have experienced a cardiac event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in HbA1c From Baseline Over Time</measure>
    <time_frame>Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168</time_frame>
    <description>To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Fasting Plasma Glucose Over Time</measure>
    <time_frame>Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168</time_frame>
    <description>To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</measure>
    <time_frame>24 week</time_frame>
    <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</measure>
    <time_frame>Duration of study (168 weeks)</time_frame>
    <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</measure>
    <time_frame>Duration of study (168 weeks)</time_frame>
    <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Participants With Incidence of Hospitalization for Heart Failure</measure>
    <time_frame>Duration of study (168 weeks)</time_frame>
    <description>To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1700</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin tablets, 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>20 mg, tablet</description>
    <arm_group_label>Bexagliflozin tablets, 20 mg</arm_group_label>
    <other_name>EGT0001442</other_name>
    <other_name>EGT0001474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 mg tablet to match active comparator</description>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a diagnosis of T2DM&#xD;
&#xD;
          -  Subjects who have had a stable treatment regimen for T2DM for the past 3 months&#xD;
&#xD;
          -  Subjects who present with at least one of the following 3 histories:&#xD;
&#xD;
        Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure&#xD;
        Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently&#xD;
        smoking, reduced kidney function, or cholesterol problems&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young&#xD;
&#xD;
          -  History of genitourinary tract infections&#xD;
&#xD;
          -  Evidence of abnormal liver function&#xD;
&#xD;
          -  History of MI, stroke or hospitalization for heart failure in the past 3 months&#xD;
&#xD;
          -  Prior kidney transplant or evidence of kidney problems&#xD;
&#xD;
          -  Prior or planned pace maker implantation&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Paul Lock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theracos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site 1090</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1041</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1073</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1076</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1078</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1089</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <zip>90710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1058</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1051</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1004</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1068</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1077</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1218</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1092</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1216</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1083</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1057</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1059</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1050</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1099</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1066</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1072</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1082</name>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <zip>83201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1258</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1043</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1071</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1086</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1224</name>
      <address>
        <city>Covington</city>
        <state>Kentucky</state>
        <zip>41011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1228</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1221</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1079</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1223</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1217</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1254</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1054</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1060</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1252</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1052</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1263</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1080</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1219</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1044</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1264</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1220</name>
      <address>
        <city>Saratoga Springs</city>
        <state>New York</state>
        <zip>12866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1049</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1085</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1074</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1056</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1229</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1064</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1075</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1266</name>
      <address>
        <city>Lindsay</city>
        <state>Oklahoma</state>
        <zip>73052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1055</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1265</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1046</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1260</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1042</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1225</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1259</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1048</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1070</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1222</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1081</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1226</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1053</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1063</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1230</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5013</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5015</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5012</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5023</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5016</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5005</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3C 5K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5022</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5014</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XS</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5008</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5007</name>
      <address>
        <city>St-Charles-Borromee</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5009</name>
      <address>
        <city>St. Georges</city>
        <state>Quebec</state>
        <zip>G5Y4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5006</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3116</name>
      <address>
        <city>Benesov</city>
        <zip>256 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3106</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3107</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3118</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3109</name>
      <address>
        <city>Cesky Krumlov</city>
        <zip>381 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3114</name>
      <address>
        <city>Havirov</city>
        <zip>736 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3103</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3110</name>
      <address>
        <city>Krnov</city>
        <zip>794 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3102</name>
      <address>
        <city>Kromeriz</city>
        <zip>767 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3105</name>
      <address>
        <city>Marianske Lazne</city>
        <zip>353 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3113</name>
      <address>
        <city>Plzen</city>
        <zip>326 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3104</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3111</name>
      <address>
        <city>Praha</city>
        <zip>149 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3112</name>
      <address>
        <city>Praha</city>
        <zip>181 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3115</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 68</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6104</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6103</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300S</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6105</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7007</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-Do</state>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7001</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-Do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7004</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7005</name>
      <address>
        <city>Guri</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7006</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7002</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7008</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2015</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2013</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2008</name>
      <address>
        <city>Tampico</city>
        <state>Tamaulipas</state>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2012</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2011</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2009</name>
      <address>
        <city>Chihuahua</city>
        <zip>31217</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2014</name>
      <address>
        <city>Mexico</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2016</name>
      <address>
        <city>Queretaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2010</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5110</name>
      <address>
        <city>Amsterdam</city>
        <zip>2545CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5113</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5101</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5223GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5112</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5102</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5106</name>
      <address>
        <city>Rotterdam</city>
        <zip>3O45 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5103</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7122</name>
      <address>
        <city>Aleksandrow Lodzki</city>
        <zip>95-070</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7113</name>
      <address>
        <city>Gdansk</city>
        <zip>80-126</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7119</name>
      <address>
        <city>Gdynia</city>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7109</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7115</name>
      <address>
        <city>Katowice</city>
        <zip>20-060</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7106</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7121</name>
      <address>
        <city>Katowice</city>
        <zip>40-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7111</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7104</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7135</name>
      <address>
        <city>Lodz</city>
        <zip>94-255</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7120</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7108</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7118</name>
      <address>
        <city>Otwock</city>
        <zip>05-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7107</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7105</name>
      <address>
        <city>Sobotka</city>
        <zip>55-050</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7112</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7123</name>
      <address>
        <city>Warsaw</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7117</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7116</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9309</name>
      <address>
        <city>Lomonosov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9303</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9315</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9314</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9318</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9301</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9310</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>1199044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9304</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9307</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9311</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9312</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9302</name>
      <address>
        <city>Tomsk</city>
        <zip>6340</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8001</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8002</name>
      <address>
        <city>New Taipei</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8006</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8005</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8007</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8004</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8003</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02558296/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1700 patients were recruited from 10 countries: Canada, Czech Republic, Demark, Republic of Korea, Mexico, the Netherlands, Poland, Russian Federation, Taiwan, and the United States.</recruitment_details>
      <pre_assignment_details>Subjects ≥ 40 years old with inadequately controlled T2DM with HbA1c between 7.5% (7.0% since protocol version 8) and 11% on stable medications and elevated risk for CV adverse events were enrolled. All subjects must belong to 1 of 3 CV risk groups to be eligible. All eligible subjects took placebo during 13 ± 2 days run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
        </group>
        <group group_id="P2">
          <title>Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed the Study Through Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1133"/>
                <participants group_id="P2" count="567"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="542"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The subject was randomized, but did not take any investigational product</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed the Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1133"/>
                <participants group_id="P2" count="567"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="987"/>
                <participants group_id="P2" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The subject was randomized, but did not take any investigational product</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1133"/>
            <count group_id="B2" value="567"/>
            <count group_id="B3" value="1700"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="562"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="838"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="7.94"/>
                    <measurement group_id="B2" value="64.6" spread="8.01"/>
                    <measurement group_id="B3" value="64.4" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="518"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="792"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="1182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="967"/>
                    <measurement group_id="B2" value="474"/>
                    <measurement group_id="B3" value="1441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="879"/>
                    <measurement group_id="B2" value="430"/>
                    <measurement group_id="B3" value="1309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Risk Groups</title>
          <description>1: History of atherosclerotic vascular disease with &gt; 1 of the following: i) MI/ischemic stroke &gt; 3 months but &lt; 5 years prior to screening ii) Documented history of coronary, carotid or peripheral arterial revascularization (CABG must have occurred &gt; 5 years prior to screening) 2: History of heart failure 3: Age &gt;= 55 with &gt; 2 of the following: i) Diabetes duration of &gt; 10 years ii) Uncontrolled hypertension defined as SBP &gt; 140 mmHg despite &gt; 3 anti-hypertensive medications iii) current smoker iv) Urine albumin: creatinine ratio &gt; 30 mg/g v) eGFR 45-60 mL/min/1.73 m2 vi) HDL &lt; 1 mmol/L</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Group 1: History of atherosclerotic vascular disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="703"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="1065"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Group 2: History of heart failure</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Group 3: Age &gt;= 55 years with &gt; 2 risk factors</title>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.59" spread="21.87"/>
                    <measurement group_id="B2" value="92.62" spread="19.999"/>
                    <measurement group_id="B3" value="93.94" spread="20.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.80" spread="6.068"/>
                    <measurement group_id="B2" value="32.24" spread="5.751"/>
                    <measurement group_id="B3" value="32.62" spread="5.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index Categories</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>BMI &lt; 25 kg/m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BMI &gt;= 25 kg/m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1047"/>
                    <measurement group_id="B2" value="522"/>
                    <measurement group_id="B3" value="1569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.2" spread="16.24"/>
                    <measurement group_id="B2" value="133.7" spread="16.18"/>
                    <measurement group_id="B3" value="134.0" spread="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure Groups</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 140 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="685"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="1037"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 140 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.1" spread="9.94"/>
                    <measurement group_id="B2" value="76.8" spread="10.16"/>
                    <measurement group_id="B3" value="77.0" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR at Screening</title>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.93" spread="19.475"/>
                    <measurement group_id="B2" value="77.76" spread="19.653"/>
                    <measurement group_id="B3" value="77.88" spread="19.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 60 mL/min/1.73 m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 60 mL/min/1.73 m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="908"/>
                    <measurement group_id="B2" value="458"/>
                    <measurement group_id="B3" value="1366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.32" spread="0.897"/>
                    <measurement group_id="B2" value="8.33" spread="0.944"/>
                    <measurement group_id="B3" value="8.32" spread="0.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;= 8.5%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="716"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="1078"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 8.5%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="417"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes from Diagnosis to the date of informed consent</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.87" spread="8.635"/>
                    <measurement group_id="B2" value="15.23" spread="9.253"/>
                    <measurement group_id="B3" value="14.99" spread="8.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Use at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="610"/>
                    <measurement group_id="B2" value="292"/>
                    <measurement group_id="B3" value="902"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="523"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Anti-Diabetic Treatment at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1125"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1689"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NT-proBNP</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="391.9" spread="760.75"/>
                    <measurement group_id="B2" value="264.0" spread="427.15"/>
                    <measurement group_id="B3" value="346.1" spread="661.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <units>% of Left Ventricular Ejection Fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="14.13"/>
                    <measurement group_id="B2" value="50.8" spread="12.95"/>
                    <measurement group_id="B3" value="49.8" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 24</title>
        <description>The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of subjects with a value at baseline and at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 24</title>
          <description>The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.</description>
          <population>Number of subjects with a value at baseline and at Week 24.</population>
          <units>percentage of glycated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1046"/>
                <count group_id="O2" value="531"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" lower_limit="-0.90" upper_limit="-0.80"/>
                    <measurement group_id="O2" value="-0.37" lower_limit="-0.44" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the primary endpoint was that the mean change in HbA1c from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 24 was less than the mean change in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin</title>
        <description>To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of subjects with a value at baseline and at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin</title>
          <description>To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes</description>
          <population>Number of subjects with a value at baseline and at week 24.</population>
          <units>Percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="561"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" lower_limit="-0.92" upper_limit="-0.77"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-0.43" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the secondary endpoint was that the mean change in HbA1c from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 24 was less than the mean change in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories, history of heart failure, treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline to Week 48</title>
        <description>To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo</description>
        <time_frame>48 weeks</time_frame>
        <population>Number of subjects with a value at baseline and at Week 48 is included.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline to Week 48</title>
          <description>To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo</description>
          <population>Number of subjects with a value at baseline and at Week 48 is included.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="922"/>
                <count group_id="O2" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" lower_limit="-3.27" upper_limit="-2.80"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.72" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the secondary endpoint was that the mean change in body weight from baseline to Week 48 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in body weight from baseline to Week 48 was less than the mean change in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is presented based on one-sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline HbA1c and eGFR, history of heart failure, insulin use (Y/N), treatment, visit and baseline body weight as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.07</ci_lower_limit>
            <ci_upper_limit>-2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline</title>
        <description>To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of subjects with a value at baseline and at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline</title>
          <description>To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo</description>
          <population>Number of subjects with a value at baseline and at week 24</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.83" lower_limit="-11.28" upper_limit="-8.38"/>
                    <measurement group_id="O2" value="-6.87" lower_limit="-8.95" upper_limit="-4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the secondary endpoint was that the mean change in systolic blood pressure from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in systolic blood pressure from baseline to Week 24 was less than the mean change in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>0.0112</p_value>
            <p_value_desc>P-value is presented based on one-sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline HbA1c, GFR categories, BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline SBP as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.51</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in HbA1c From Baseline Over Time</title>
        <description>To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks</description>
        <time_frame>Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168</time_frame>
        <population>Number of subjects with a value at baseline and at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline Over Time</title>
          <description>To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks</description>
          <population>Number of subjects with a value at baseline and at the specified visit.</population>
          <units>Percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1111"/>
                    <count group_id="O2" value="553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-0.72" upper_limit="-0.65"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-0.28" upper_limit="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1075"/>
                    <count group_id="O2" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-0.94" upper_limit="-0.85"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-0.39" upper_limit="-0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1046"/>
                    <count group_id="O2" value="531"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" lower_limit="-0.89" upper_limit="-0.79"/>
                    <measurement group_id="O2" value="-0.37" lower_limit="-0.45" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1017"/>
                    <count group_id="O2" value="511"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-0.92" upper_limit="-0.81"/>
                    <measurement group_id="O2" value="-0.39" lower_limit="-0.47" upper_limit="-0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                    <count group_id="O2" value="496"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" lower_limit="-0.90" upper_limit="-0.79"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.46" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="965"/>
                    <count group_id="O2" value="469"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" lower_limit="-0.83" upper_limit="-0.70"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-0.44" upper_limit="-0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="874"/>
                    <count group_id="O2" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" lower_limit="-0.75" upper_limit="-0.62"/>
                    <measurement group_id="O2" value="-0.29" lower_limit="-0.39" upper_limit="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="768"/>
                    <count group_id="O2" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-0.73" upper_limit="-0.58"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-0.33" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-0.71" upper_limit="-0.53"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-0.37" upper_limit="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" lower_limit="-0.67" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-0.29" lower_limit="-0.46" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 6 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 6 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 12 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 12 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 24 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 36 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 36 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 48 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 48 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 72 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 72 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 96 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 96 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 120 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 120 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 144 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 144 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in HbA1c from baseline to Week 168 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline HbA1c from baseline to Week 168 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>0.0045</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Fasting Plasma Glucose Over Time</title>
        <description>To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks</description>
        <time_frame>Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168</time_frame>
        <population>Number of subjects with a value at baseline and at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose Over Time</title>
          <description>To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks</description>
          <population>Number of subjects with a value at baseline and at the specified visit.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1107"/>
                    <count group_id="O2" value="552"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" lower_limit="-1.40" upper_limit="-1.16"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.10" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1078"/>
                    <count group_id="O2" value="545"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" lower_limit="-1.46" upper_limit="-1.21"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.12" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1045"/>
                    <count group_id="O2" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" lower_limit="-1.56" upper_limit="-1.30"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.23" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1016"/>
                    <count group_id="O2" value="513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" lower_limit="-1.36" upper_limit="-1.06"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.27" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="996"/>
                    <count group_id="O2" value="494"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-1.50" upper_limit="-1.21"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.33" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="966"/>
                    <count group_id="O2" value="469"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-1.30" upper_limit="-0.98"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-0.38" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="873"/>
                    <count group_id="O2" value="425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" lower_limit="-1.32" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.20" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="765"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" lower_limit="-1.09" upper_limit="-0.71"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-0.02" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" lower_limit="-1.24" upper_limit="-0.81"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-0.72" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" lower_limit="-1.39" upper_limit="-0.73"/>
                    <measurement group_id="O2" value="-0.55" lower_limit="-1.04" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 6 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 6 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 12 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 12 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 24 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 36 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 36 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 48 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 48 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>-0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 72 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 72 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 96 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 96 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>-0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 120 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 120 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 144 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 144 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>0.0008</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for the exploratory endpoint was that the mean change in FPG from baseline to Week 168 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Rejection of the null hypothesis would imply that the mean change in baseline FPG from baseline to Week 168 was less than that in the placebo arm by a value that could not be attributed to chance alone.</non_inferiority_desc>
            <p_value>0.0462</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</title>
        <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
        <time_frame>24 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</title>
          <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
            <estimate_desc>Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</title>
        <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period</description>
        <time_frame>Duration of study (168 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification</title>
          <description>To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Hazard ratio and p-value were estimated using Cox regression model for time to first event in the bexagliflozin arm vs. placebo arm during entire study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</title>
        <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</title>
          <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.08" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
            <estimate_desc>Odds ratio is calculated as the ratio of bexagliflozin over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</title>
        <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study</description>
        <time_frame>Duration of study (168 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent</title>
          <description>To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.08" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
            <estimate_desc>Hazard ratio and p-value were estimated using Cox regression model for time to first event in the bexagliflozin arm vs. placebo arm during the entire study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Participants With Incidence of Hospitalization for Heart Failure</title>
        <description>To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline</description>
        <time_frame>Duration of study (168 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects: Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
This group includes all subjects who have received bexagliflozin in the study.</description>
          </group>
          <group group_id="O2">
            <title>All Subjects: Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator&#xD;
This group includes all subjects who have received placebo in the study.</description>
          </group>
          <group group_id="O3">
            <title>Subjects With HF History: Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
This group includes subjects who reported a history of heart failure and randomized to the bexagliflozin arm.</description>
          </group>
          <group group_id="O4">
            <title>Subjects With HF History: Placebo</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator&#xD;
This group includes subjects who reported a history of heart failure and randomized to the placebo arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Incidence of Hospitalization for Heart Failure</title>
          <description>To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="567"/>
                <count group_id="O3" value="302"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O4" value="0.09" lower_limit="0.05" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0803</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0272</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0757</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Hazard ratio and p-value were estimated using Cox regression model for treatment comparison vs. placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0273</p_value>
            <p_value_desc>P-value is based on one sided statistical tests using a 0.025 level of significance.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Region, baseline eGFR categories &amp; BMI, history of heart failure, insulin use (Y/N), treatment and baseline HbA1c as fixed effect covariate.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Hazard ratio and p-value were estimated using Cox regression model for treatment comparison vs. placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the first dose to the last day of follow up (4 weeks after the End of Treatment visit, an average of 127 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for the duration of the study.&#xD;
Placebo: 20 mg tablet to match active comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1132"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="373" subjects_at_risk="1132"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="1132"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="1132"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="1132"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="1132"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="1132"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1132"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="1132"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1132"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Anginal equivalent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Corneal lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Barret's oesophagus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1132"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1132"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Emphysematous cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1132"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Latent autoimmune diabetes in adults</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Immunoglobulin G4 related sclerosing disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Biliary cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Colon cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1132"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1132"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cerebral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Miller Fisher syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1132"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1132"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Acute pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Prophylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1132"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="1132"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="739" subjects_at_risk="1132"/>
                <counts group_id="E2" subjects_affected="386" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="90" subjects_affected="72" subjects_at_risk="1132"/>
                <counts group_id="E2" events="40" subjects_affected="31" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="54" subjects_at_risk="1132"/>
                <counts group_id="E2" events="45" subjects_affected="37" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="65" subjects_affected="52" subjects_at_risk="1132"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="115" subjects_affected="96" subjects_at_risk="1132"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="147" subjects_affected="112" subjects_at_risk="1132"/>
                <counts group_id="E2" events="82" subjects_affected="53" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="190" subjects_affected="128" subjects_at_risk="1132"/>
                <counts group_id="E2" events="96" subjects_affected="60" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="53" subjects_affected="49" subjects_at_risk="1132"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="181" subjects_affected="68" subjects_at_risk="1132"/>
                <counts group_id="E2" events="80" subjects_affected="41" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3743" subjects_affected="475" subjects_at_risk="1132"/>
                <counts group_id="E2" events="1857" subjects_affected="246" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="49" subjects_at_risk="1132"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="567"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="72" subjects_affected="66" subjects_at_risk="1132"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="46" subjects_affected="45" subjects_at_risk="1132"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="567"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 630-2129</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

